Cynthia Ordaz-Pichardo

Dr. Cynthia Ordaz-Pichardo

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2006 in Clinical Medicine & Research
Verified
Journal Article
Open access
PDF file
Nidia Leon-SicairosNidia Leon-Sicairos
Nidia Leon-Sicairos
FLFernando López-Soto
Fernando López-Soto
MRMagda Reyes-López
Magda Reyes-López
DGDelfino Godínez-Vargas
Delfino Godínez-Vargas
COCynthia Ordaz-Pichardo
Cynthia Ordaz-Pichardo
MAMireya De la Garza Amaya
Mireya De la Garza Amaya
Objectives: To identify amoebicidal components in human milk and the effect of iron on the amoebicidal activity.

1 June 2006 in Biochemistry and Cell Biology
Verified
Journal Article
Closed access
Nidia Leon-SicairosNidia Leon-Sicairos
Nidia Leon-Sicairos
MRMagda Reyes-Lópezm. Reyes-López
Magda Reyes-Lópezm. Reyes-López
COCynthia Ordaz-Pichardo
Cynthia Ordaz-Pichardo
MAMireya De la Garza Amaya
Mireya De la Garza Amaya
Lactoferrin (Lf), in its iron-free form, has been shown to inhibit the growth of pathogenic microorganisms. In the light of new agents to control amoebiasis, the microbicidal activity of human and bovine Lf and bovine lactoferricin (bLfcin, fragment 4–14), and of each combined with metronidazole, the main drug used in amoebiasis, was evaluated in trophozoites of Entamoeba histolytica. Both lactoferrins and bLfcin were able to kill amoebas in a concentration-dependent manner. This killing effect was modulated according to the culture age, pH, and temperature. Parasites obtained from the stationary phase were more susceptible to Lf than those from the early exponential phase. The effect of Lf and its derived peptide, bLfcin, was prevented by both Fe2+ and Fe3+. However, the divalent cations Mg2+ and Ca2+ prevented the killing effect of Lf but not of bLfcin. A synergistic amoebicidal effect was found between metronidazole and human Lf, bovine Lf, or bLfcin. These data suggest that Lf and bLfcin might be used in amoebiasis if they are administered with a low dose of metronidazole to diminish the toxicity of this drug. Thus, Lf and bLfcin are therapeutically potential candidates for use as antiamoebics in patients.

27 July 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
MMMaria Monica Michicotl Meneses
Maria Monica Michicotl Meneses
MTMaria del Rocio Thompson-Bonilla
Maria del Rocio Thompson-Bonilla
CRCesar A Reyes-Lopez
Cesar A Reyes-Lopez
Blanca Estela García-PérezBlanca Estela García-Pérez
Blanca Estela García-Pérez
ILItzel Ivonn López
Itzel Ivonn López
MJMaria Jaramillo-Flores
Maria Jaramillo-Flores
Pomegranate juice (Punica granatum) has been used since ancient times in traditional medicine (Unani Medicine, Ayurveda); its main compounds are anthocyanins and ellagic acid, which have anti-inflammatory, antioxidant, hepatoprotective, and cardiovascular health effects. The objective was to evaluate the effect of pomegranate juice on inflammation, blood pressure, and vascular and physiological markers associated with obesity induced by a high-fat diet in a murine model. The results show that pomegranate juice reduces the concentration of low-density lipoprotein cholesterol (cLDL) 39% and increases the concentration of high-density lipoprotein cholesterol (cHDL) by 27%, leading to a 12%–18% decrease in the risk of cardiovascular diseases (CVD). In addition to reducing blood pressure by 24%, it also had an antiatherogenic effect by decreasing sE-selectin levels by 42%. On the other hand, the juice significantly increased adiponectin levels in adipose tissue, decreased levels of inflammation markers (tumor necrosis factor-α (TNF-α), plasminogen activator inhibitor-1 (PAI-1), interleukin-17A (IL-17A), interleukin-6 (IL-6), interleukin-1β (IL-1β)), and inhibited the monocyte chemoattractant protein-1 (MCP-1). Pomegranate juice requires clinical studies to prove its immunoregulatory and therapeutic effects on cardiovascular and atherogenic risks.

1 September 2009 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
Gildardo RiveraGildardo Rivera
Gildardo Rivera
VBVirgilio Bocanegra-Garcia
Virgilio Bocanegra-Garcia
COCynthia Ordaz-Pichardo
Cynthia Ordaz-Pichardo
BNBenjamin Nogueda-Torres
Benjamin Nogueda-Torres
AMAntonio Monge
Antonio Monge
Chagas disease is one of the most important parasitic diseases in Latin America, affecting16 to 18 million people. Nifurtimox and Benznidazol are drugs that are commonly used in its treatment; however, these drugs produce several adverse reactions and are not effective in the chronic phase of the disease. Therefore, the design, synthesis, and biological evaluation of new compounds with potential activity against Trypanozoma cruzi are of great importance. We review six proteins involved in the biochemical metabolism of Trypanosoma cruzi that have recently been studied as potential targets for designing new drugs for Chagas disease. These are farnesyl pyrophosphate synthase, trans-sialidase, cruzain cystein protease, trypanothione reductase, glucose 6-phosphate-dehydrogenase, glyceraldehyde 3-phosphatedehydrogenase, and α-hydroxy acid dehydrogenase. We also review the advances of compounds recently designed based on structure-activity, and the perspectives of new compounds that inhibit these therapeutic targets.

1 December 2009 in Infection, Genetics and Evolution
Verified
Journal Article
Closed access
FLFernando López-Soto
Fernando López-Soto
Nidia Leon-SicairosNidia Leon-Sicairos
Nidia Leon-Sicairos
MRMagda Reyes-López
Magda Reyes-López
JSJesús Serrano-Luna
Jesús Serrano-Luna
COCynthia Ordaz-Pichardo
Cynthia Ordaz-Pichardo
MGMireya de la Garza
Mireya de la Garza

1 August 2016 in Biochimica et Biophysica Acta (BBA) - Biomembranes
Verified
Journal Article
Closed access
Cerecedo DorisCerecedo Doris
Cerecedo Doris
IMIvette Martínez-Vieyra
Ivette Martínez-Vieyra
ASAlejandro Sosa-Peinado
Alejandro Sosa-Peinado
JCJorge Cornejo-Garrido
Jorge Cornejo-Garrido
COCynthia Ordaz-Pichardo
Cynthia Ordaz-Pichardo
CBClaudia Guadalupe Benítez-Cardoza
Claudia Guadalupe Benítez-Cardoza